Lymphoma News

NEW ORLEANS — Lisocabtagene maraleucel can be administered safely in the community setting to patients relapsed or refractory large B-cell lymphoma, according to phase 2 study results.

Healio spoke with Joshua Brody, MD, about unmet needs and distinct challenges, as well as the treatment landscape in diffuse large B-cell lymphoma.

Healio spoke with Joshua Brody, MD, about unmet needs and distinct challenges, as well as the treatment landscape in diffuse large B-cell lymphoma.

Healio spoke with Joshua Brody, MD, about unmet needs and distinct challenges, as well as the treatment landscape in diffuse large B-cell lymphoma.

Healio spoke with Joshua Brody, MD, about unmet needs and distinct challenges, as well as the treatment landscape in diffuse large B-cell lymphoma.

Healio spoke with Joshua Brody, MD, about unmet needs and distinct challenges, as well as the treatment landscape in diffuse large B-cell lymphoma.

Healio spoke with Joshua Brody, MD, about unmet needs and distinct challenges, as well as the treatment landscape in diffuse large B-cell lymphoma.

The FDA announced several regulatory actions the past few weeks.

NEW ORLEANS — A novel chimeric antigen receptor T-cell therapy showed encouraging early efficacy among heavily pretreated patients with CD19-positive non-Hodgkin lymphoma, according to study results.

NEW ORLEANS — Bendamustine lymphodepletion resulted in significant CAR T-cell expansion among patients with relapsed or refractory non-Hodgkin lymphoma, according to study results presented at ASH Annual Meeting and Exposition.